Weight-loss jabs could prevent and treat addiction to alcohol, cigarettes and drugs, according to a large study. Experts believe the way the medicines work on the brain’s reward pathway cuts cravings ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health conditions. Clinical trials show that people can lose up to 20 percent of ...

New research has found that people taking medications such as Mounjaro or Wegovy for weight loss purposes may regain the majority of the weight they lost when they stop taking it. The jabs, also known ...

The MarketWatch News Department was not involved in the creation of this content. -- Average weight loss of 17% if all patients stayed on treatment* with Wegovy(R) (semaglutide) tablets 25 mg (14% ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has approved the first GLP-1 pill for weight loss and maintenance. Drugmaker Novo Nordisk ...

You might already know the short-term effects, like appetite control and weight loss. But what about the long-term side effects of Wegovy®? Long-term effects are rare but can include an increased risk ...

Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

Fatty liver disease happens when too much fat builds up in the liver. Metabolic dysfunction-associated steatohepatitis (MASH) is a severe type of fatty liver disease where fat buildup causes liver ...

The pharmaceutical giant Novo Nordisk has claimed that its new weight loss pill will do amazing things for the 100 million Americans living with obesity. However, a study published in January throws ...

In OASIS 4, common adverse reactions were similar to those previously seen in clinical trials with Wegovy® (semaglutide) injection 2.4 mg, including nausea, diarrhea, and vomiting.1 The starting dose ...